Postherpetic Granulomatous Dermatitis in a Man Treated With Nivolumab

Martín-Carrasco, P.; Pérez-Ruiz, C.; Zulueta‐Dorado, Teresa; Conejo‐Mir, Julián

doi:10.1016/j.adengl.2017.07.006

Cited by 7 publications

(18 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most cases of HZ can be diagnosed clinically . Post VZV‐GD is the most frequent type within a variety of cutaneous reactions that can appear in the area in which a reactivation of this virus takes place . The formation of granulomas may be because of a delayed hypersensitivity reaction to viral envelope glycoproteins.…”

Section: Discussionmentioning

confidence: 99%

“…The formation of granulomas may be because of a delayed hypersensitivity reaction to viral envelope glycoproteins. These reactions have occurred in patients with lymphoproliferative syndromes, related in these cases to alterations in the number and function of immunoglobulins, cellular immunity and the increase in hypersensitivity reactions …”

Section: Discussionmentioning

confidence: 99%

“…Nivolumab strengthens T cell responses, including antitumor responses . Some authors have postulated that nivolumab stimulated T cells, which promoted hypersensitivity reactions and the formation of granulomas to VZV envelope glycoproteins, triggering VZV‐GD.…”

Section: Discussionmentioning

confidence: 99%

“…Varicella‐zoster virus (VZV‐GD) is a cutaneous reaction that can appear in the area in which a reactivation of the VZV takes place. It may occur during treatment with ICIs but very few cases are described in the literature …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report

et al. 2020

View full text Add to dashboard Cite

Granulomatous dermatitis (GD) is the most common among a variety of skin reactions that may occur in the varicella-zoster virus (VZV) reactivation area. It is thought that the formation of granulomas may be the result of a delayed hypersensitivity reaction to viral envelope glycoproteins. Immune checkpoint inhibitors (ICIs), such as nivolumab stimulate T cells and promote hypersensitivity reactions, leading to the formation of granulomas in VZV wrapping proteins, thus triggering VZV-GD. Few cases of the use of ICIs in patients diagnosed with VZV-GD have been reported in the literature. Here, we report the clinical case of a patient with metastatic lung cancer which was treated with nivolumab who subsequently developed VZV-GD. Accurate clinical diagnosis and prompt treatment with antiviral agents have resulted in a complete resolution of the clinical picture.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These side‐effects present with a broad spectrum of severity, some requiring cessation of therapy and use of immunosuppressive agents . The immune damage after anti‐PD‐1 immunotherapy can generate granulomatous inflammation, with cases reported of sarcoidosis‐like granulomatous inflammatory reaction in pleura, kidney and skin . Other reports describe granulomatous panniculitis .…”

Section: Introductionmentioning

confidence: 99%

Granulomatous and lichenoid dermatitis after IgG4 anti‐PD‐1 monoclonal antibody therapy for advanced cancer

et al. 2018

View full text Add to dashboard Cite

Nivolumab is a fully human IgG4 monoclonal antibody directed against programmed cell death protein 1 (PD-1). PD-1 inhibition allows T-cell activation and recruitment to destroy cancer cells. Checkpoint inhibitors have shown significant survival advantage and relatively low side-effects in comparison with conventional chemotherapy in several types of advanced cancer. Granulomatous cutaneous reactions have been reported showing sarcoidal and panniculitic morphology. Here we present a case of drug-induced lichenoid and granulomatous dermatitis after checkpoint inhibitor therapy observed in a 63-year-old male treated with nivolumab for advanced glioblastoma. This morphology has not been previously reported. We documented a high number of CD8+ T-cells within the lesions. Additionally, we review the side-effects observed with the use of checkpoint inhibitors, with special focus on cutaneous manifestations.

show abstract

Postherpes zoster programmed death-1 inhibitor−associated zosteriform granulomatous reactions

et al. 2020

View full text Add to dashboard Cite

Postherpetic Granulomatous Dermatitis in a Man Treated With Nivolumab

Cited by 7 publications

References 12 publications

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report

Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report

Granulomatous and lichenoid dermatitis after IgG4 anti‐PD‐1 monoclonal antibody therapy for advanced cancer

Postherpes zoster programmed death-1 inhibitor−associated zosteriform granulomatous reactions

Contact Info

Product

Resources

About